Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given $29.63 Consensus Target Price by Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have been assigned an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price target of $29.63 for the company and are predicting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Milestone Pharmaceuticals an industry rank of 63 out of 256 based on the ratings given to its competitors.

MIST has been the topic of a number of analyst reports. Cowen initiated coverage on shares of Milestone Pharmaceuticals in a report on Monday, June 3rd. They issued an “outperform” rating and a $32.00 price objective on the stock. Piper Jaffray Companies initiated coverage on shares of Milestone Pharmaceuticals in a report on Monday, June 3rd. They issued an “overweight” rating and a $26.50 price objective on the stock. Jefferies Financial Group initiated coverage on shares of Milestone Pharmaceuticals in a report on Monday, June 3rd. They issued a “buy” rating and a $28.00 price objective on the stock. Oppenheimer initiated coverage on shares of Milestone Pharmaceuticals in a report on Tuesday, June 4th. They issued an “outperform” rating and a $32.00 price objective on the stock. Finally, CIBC initiated coverage on shares of Milestone Pharmaceuticals in a report on Tuesday, June 4th. They issued an “outperform” rating and a $32.00 price objective on the stock.

Shares of MIST opened at $27.15 on Friday. Milestone Pharmaceuticals has a twelve month low of $15.09 and a twelve month high of $27.95. The firm has a fifty day moving average price of $20.63.

In related news, major shareholder Holdings A/S Novo bought 333,333 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $15.00 per share, with a total value of $4,999,995.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Rtw Investments, Lp bought 666,667 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $10,000,005.00. The disclosure for this purchase can be found here.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Featured Article: Systematic Risk

Get a free copy of the Zacks research report on Milestone Pharmaceuticals (MIST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.